Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
CMAJ ; 194(9): E350-E360, 2022 03 07.
Article in French | MEDLINE | ID: covidwho-1731613

ABSTRACT

CONTEXTE: La pandémie de COVID-19 a affecté de manière disproportionnée les travailleurs de la santé. Nous avons voulu mesurer la séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé dans les hôpitaux du Québec, au Canada, après la première vague de la pandémie, afin d'explorer les facteurs associés à la SRAS-CoV-2-séropositivité. MÉTHODES: Entre le 6 juillet et le 24 septembre 2020, nous avons recruté des travailleurs de la santé de 10 hôpitaux, dont 8 d'une région où l'incidence de la COVID-19 était élevée (région de Montréal) et 2 de régions du Québec où l'incidence était faible. Les travailleurs de la santé admissibles étaient des médecins, des infirmières, des préposées aux bénéficiaires et des préposés à l'entretien ménager travaillant dans 4 types d'unité de soins (urgences, soins intensifs, unité hospitalière COVID-19 et unité hospitalière non-COVID-19). Les participants ont répondu à un questionnaire et subi un dépistage sérologique du SRAS-CoV-2. Nous avons identifié les facteurs ayant un lien indépendant avec une séroprévalence plus élevée. RÉSULTATS: Parmi les 2056 travailleurs de la santé recrutés, 241 (11,7 %) se sont révélés SRAS-CoV-2-positifs. Parmi eux, 171 (71,0 %) avaient déjà reçu un diagnostic de COVID-19. La séroprévalence a varié d'un hôpital à l'autre, de 2,4 %­3,7 % dans les régions où l'incidence était faible, à 17,9 %­32,0 % dans les hôpitaux ayant connu des éclosions touchant 5 travailleurs de la santé ou plus. La séroprévalence plus élevée a été associée au fait de travailler dans un hôpital où des éclosions sont survenues (rapport de prévalence ajusté 4,16, intervalle de confiance [IC] à 95 % 2,63­6,57), au fait d'être infirmière ou auxiliaire (rapport de prévalence ajusté 1,34, IC à 95 % 1,03­1,74), préposée aux bénéficiaires (rapport de prévalence ajusté 1,49, IC à 95 % 1,12­1,97) et d'ethnicité noire ou hispanique (rapport de prévalence ajusté 1,41, IC à 95 % 1,13­1,76). La séroprévalence moindre a été associée au fait de travailler dans une unité de soins intensifs (rapport de prévalence ajusté 0,47, IC à 95 % 0,30­0,71) ou aux urgences (rapport de prévalence ajusté 0,61, IC à 95 % 0,39­0,98). INTERPRÉTATION: Les travailleurs de la santé des hôpitaux du Québec ont été exposés à un risque élevé d'infection par le SRAS-CoV-2, particulièrement lors des éclosions. Il faudra travailler à mieux comprendre la dynamique de la transmission du SRAS-CoV-2 dans les milieux de soins.


Subject(s)
Antibodies, Viral/analysis , COVID-19 Serological Testing/methods , COVID-19/epidemiology , Health Personnel/statistics & numerical data , Pandemics , SARS-CoV-2/immunology , Seroepidemiologic Studies , Adult , COVID-19/diagnosis , COVID-19/virology , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Quebec/epidemiology , Retrospective Studies
2.
CMAJ ; 193(49): E1868-E1877, 2021 12 13.
Article in English | MEDLINE | ID: covidwho-1591952

ABSTRACT

BACKGROUND: The COVID-19 pandemic has disproportionately affected health care workers. We sought to estimate SARS-CoV-2 seroprevalence among hospital health care workers in Quebec, Canada, after the first wave of the pandemic and to explore factors associated with SARS-CoV-2 seropositivity. METHODS: Between July 6 and Sept. 24, 2020, we enrolled health care workers from 10 hospitals, including 8 from a region with a high incidence of COVID-19 (the Montréal area) and 2 from low-incidence regions of Quebec. Eligible health care workers were physicians, nurses, orderlies and cleaning staff working in 4 types of care units (emergency department, intensive care unit, COVID-19 inpatient unit and non-COVID-19 inpatient unit). Participants completed a questionnaire and underwent SARS-CoV-2 serology testing. We identified factors independently associated with higher seroprevalence. RESULTS: Among 2056 enrolled health care workers, 241 (11.7%) had positive SARS-CoV-2 serology. Of these, 171 (71.0%) had been previously diagnosed with COVID-19. Seroprevalence varied among hospitals, from 2.4% to 3.7% in low-incidence regions to 17.9% to 32.0% in hospitals with outbreaks involving 5 or more health care workers. Higher seroprevalence was associated with working in a hospital where outbreaks occurred (adjusted prevalence ratio 4.16, 95% confidence interval [CI] 2.63-6.57), being a nurse or nursing assistant (adjusted prevalence ratio 1.34, 95% CI 1.03-1.74) or an orderly (adjusted prevalence ratio 1.49, 95% CI 1.12-1.97), and Black or Hispanic ethnicity (adjusted prevalence ratio 1.41, 95% CI 1.13-1.76). Lower seroprevalence was associated with working in the intensive care unit (adjusted prevalence ratio 0.47, 95% CI 0.30-0.71) or the emergency department (adjusted prevalence ratio 0.61, 95% CI 0.39-0.98). INTERPRETATION: Health care workers in Quebec hospitals were at high risk of SARS-CoV-2 infection, particularly in outbreak settings. More work is needed to better understand SARS-CoV-2 transmission dynamics in health care settings.


Subject(s)
COVID-19/epidemiology , Occupational Diseases/epidemiology , SARS-CoV-2 , COVID-19/blood , COVID-19/etiology , Cross-Sectional Studies , Demography , Health Personnel , Hospitals , Humans , Incidence , Occupational Diseases/blood , Occupational Diseases/etiology , Pandemics , Quebec/epidemiology , Risk Factors , Seroepidemiologic Studies , Surveys and Questionnaires
3.
PLoS One ; 16(5): e0245031, 2021.
Article in English | MEDLINE | ID: covidwho-1314324

ABSTRACT

SARS-CoV-2 infection causing the novel coronavirus disease 2019 (COVID-19) has been responsible for more than 2.8 million deaths and nearly 125 million infections worldwide as of March 2021. In March 2020, the World Health Organization determined that the COVID-19 outbreak is a global pandemic. The urgency and magnitude of this pandemic demanded immediate action and coordination between local, regional, national, and international actors. In that mission, researchers require access to high-quality biological materials and data from SARS-CoV-2 infected and uninfected patients, covering the spectrum of disease manifestations. The "Biobanque québécoise de la COVID-19" (BQC19) is a pan-provincial initiative undertaken in Québec, Canada to enable the collection, storage and sharing of samples and data related to the COVID-19 crisis. As a disease-oriented biobank based on high-quality biosamples and clinical data of hospitalized and non-hospitalized SARS-CoV-2 PCR positive and negative individuals. The BQC19 follows a legal and ethical management framework approved by local health authorities. The biosamples include plasma, serum, peripheral blood mononuclear cells and DNA and RNA isolated from whole blood. In addition to the clinical variables, BQC19 will provide in-depth analytical data derived from the biosamples including whole genome and transcriptome sequencing, proteome and metabolome analyses, multiplex measurements of key circulating markers as well as anti-SARS-CoV-2 antibody responses. BQC19 will provide the scientific and medical communities access to data and samples to better understand, manage and ultimately limit, the impact of COVID-19. In this paper we present BQC19, describe the process according to which it is governed and organized, and address opportunities for future research collaborations. BQC19 aims to be a part of a global communal effort addressing the challenges of COVID-19.


Subject(s)
Biological Specimen Banks/organization & administration , COVID-19/pathology , COVID-19/epidemiology , COVID-19/genetics , COVID-19/metabolism , Humans , Information Dissemination/methods , Pandemics , Quebec/epidemiology , SARS-CoV-2/isolation & purification
4.
PLoS One ; 16(5): e0245031, 2021.
Article in English | MEDLINE | ID: covidwho-1234580

ABSTRACT

SARS-CoV-2 infection causing the novel coronavirus disease 2019 (COVID-19) has been responsible for more than 2.8 million deaths and nearly 125 million infections worldwide as of March 2021. In March 2020, the World Health Organization determined that the COVID-19 outbreak is a global pandemic. The urgency and magnitude of this pandemic demanded immediate action and coordination between local, regional, national, and international actors. In that mission, researchers require access to high-quality biological materials and data from SARS-CoV-2 infected and uninfected patients, covering the spectrum of disease manifestations. The "Biobanque québécoise de la COVID-19" (BQC19) is a pan-provincial initiative undertaken in Québec, Canada to enable the collection, storage and sharing of samples and data related to the COVID-19 crisis. As a disease-oriented biobank based on high-quality biosamples and clinical data of hospitalized and non-hospitalized SARS-CoV-2 PCR positive and negative individuals. The BQC19 follows a legal and ethical management framework approved by local health authorities. The biosamples include plasma, serum, peripheral blood mononuclear cells and DNA and RNA isolated from whole blood. In addition to the clinical variables, BQC19 will provide in-depth analytical data derived from the biosamples including whole genome and transcriptome sequencing, proteome and metabolome analyses, multiplex measurements of key circulating markers as well as anti-SARS-CoV-2 antibody responses. BQC19 will provide the scientific and medical communities access to data and samples to better understand, manage and ultimately limit, the impact of COVID-19. In this paper we present BQC19, describe the process according to which it is governed and organized, and address opportunities for future research collaborations. BQC19 aims to be a part of a global communal effort addressing the challenges of COVID-19.


Subject(s)
Biological Specimen Banks/organization & administration , COVID-19/pathology , COVID-19/epidemiology , COVID-19/genetics , COVID-19/metabolism , Humans , Information Dissemination/methods , Pandemics , Quebec/epidemiology , SARS-CoV-2/isolation & purification
5.
Cell Rep Med ; 1(7): 100126, 2020 10 20.
Article in English | MEDLINE | ID: covidwho-807604

ABSTRACT

SARS-CoV-2 is responsible for the coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths. The Spike glycoproteins of SARS-CoV-2 mediate viral entry and are the main targets for neutralizing antibodies. Understanding the antibody response directed against SARS-CoV-2 is crucial for the development of vaccine, therapeutic, and public health interventions. Here, we perform a cross-sectional study on 106 SARS-CoV-2-infected individuals to evaluate humoral responses against SARS-CoV-2 Spike. Most infected individuals elicit anti-Spike antibodies within 2 weeks of the onset of symptoms. The levels of receptor binding domain (RBD)-specific immunoglobulin G (IgG) persist over time, and the levels of anti-RBD IgM decrease after symptom resolution. Although most individuals develop neutralizing antibodies within 2 weeks of infection, the level of neutralizing activity is significantly decreased over time. Our results highlight the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.

SELECTION OF CITATIONS
SEARCH DETAIL